NeuroSense Therapeutics Ltd.

NRSN Nasdaq CIK: 0001875091

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation Israel
Business Address 11 HAMENOFIM ST., HERZLIYA, L3, 4672562
Mailing Address 11 HAMENOFIM ST., HERZLIYA, L3, 4672562
Phone 972-9-9531142
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
3 Initial insider ownership report April 1, 2026 View on SEC
4 Insider stock transaction report April 1, 2026 View on SEC
3 Initial insider ownership report March 31, 2026 View on SEC
20-F Foreign company annual report March 31, 2026 View on SEC
6-K Foreign company current report March 31, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
3 Initial insider ownership report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
3 Initial insider ownership report March 30, 2026 View on SEC
6-K Foreign company current report March 24, 2026 View on SEC

Annual Reports

20-F March 31, 2026
  • Successfully completed Phase IIb PARADIGM clinical trial for PrimeC
  • PrimeC demonstrated significant slowing of ALS progression in trial data
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.